{"id":71886,"date":"2026-07-30T19:02:10","date_gmt":"2026-07-30T17:02:10","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/07\/30\/t-cell-immunity-to-sars-cov-2-vaccination-in-inflammatory-bowel-disease-patients-treated-with-anti-cytokine-biologics\/"},"modified":"2026-07-30T19:02:10","modified_gmt":"2026-07-30T17:02:10","slug":"t-cell-immunity-to-sars-cov-2-vaccination-in-inflammatory-bowel-disease-patients-treated-with-anti-cytokine-biologics","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/07\/30\/t-cell-immunity-to-sars-cov-2-vaccination-in-inflammatory-bowel-disease-patients-treated-with-anti-cytokine-biologics\/","title":{"rendered":"T cell immunity to SARS-CoV-2 vaccination in inflammatory bowel disease patients treated with anti-cytokine biologics"},"content":{"rendered":"
\n

J Immunol<\/b>. 2026 Jul 10;215(7):vkag173. doi: 10.1093\/jimmun\/vkag173.<\/p>\n

ABSTRACT<\/b><\/p>\n

Anti-TNF and anti-IL-12\/IL-23 are commonly used therapies for immune-mediated inflammatory diseases (IMIDs), including inflammatory bowel disease (IBD). Although several studies have shown intact T cell responses following 2 to 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in biologics treated IMID patients, our group previously reported increased waning of T cell responses at 3-4 mos following the second vaccine dose in IMID patients compared to healthy controls, raising the possibility that a suboptimal initial T cell response could impact long term immunity. Here, to reduce patient heterogeneity, we focused only on IBD patients and further investigated T cell responses in vaccinated, untreated and biologics treated IBD patients compared to healthy controls. Following 1 vaccine dose, we observed a decreased frequency of Spike-reactive Th1 polarized cells and an increased frequency of Th2 cells in the IBD patients in general, relative to healthy controls. Additionally, IBD patients exhibited increased waning of Spike-specific cytokine T cell responses after 2 doses of vaccine. We also observed IBD-treatment specific effects. Spike-specific IL-2 secretion from anti-TNF or anti-IL-12\/IL-23-treated patients’ T cells was lower than from untreated patients following 1 dose of vaccine. However, single-cell RNA-sequencing of Spike-responsive T cells from anti-TNF and anti-IL-12\/IL-23 treated IBD patients and healthy controls 2-4 wk after 2 or 3 vaccine doses revealed no major differences in T cell subsets, transcriptomes or TCR diversity. Thus, despite some evidence of impaired primary T cell responses, Spike-reactive T cells in patients treated with anti-TNF or anti-IL-12\/IL-23 appear indistinguishable from healthy controls following a full vaccine course.<\/p>\n

PMID:42530982<\/a> | DOI:10.1093\/jimmun\/vkag173<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

J Immunol. 2026 Jul 10;215(7):vkag173. doi: 10.1093\/jimmun\/vkag173. ABSTRACT Anti-TNF and anti-IL-12\/IL-23 are commonly used therapies for immune-mediated inflammatory diseases (IMIDs), including inflammatory bowel disease (IBD). Although several studies have shown intact T cell responses following 2 to 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in biologics treated IMID patients, our group … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-71886","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/71886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=71886"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/71886\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=71886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=71886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=71886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}